First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations

Clinical trial NCT07699952 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07699952
Sponsor: Yongsheng Wang
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer (NSCLC)EGFR Activating Mutation HER2

Start date: 2026-09-09
Primary completion: 2029-03-01
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.